Explore more publications!
The Georgian Health Digest
Got News to Share?

The Georgian Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Georgian Health Digest.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 11, 2025

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
December 11, 2025

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Indeterminate GlobeNewswire
Redecan Cannabis Brand Elevates the Diamond Vape Category with the Launch of Amped Live Resin Liquid Diamond Vapes
December 11, 2025

Redecan Cannabis Brand Elevates the Diamond Vape Category with the Launch of Amped Live Resin Liquid Diamond Vapes

Indeterminate GlobeNewswire
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications 
December 11, 2025

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications 

Indeterminate GlobeNewswire
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
December 11, 2025

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Indeterminate GlobeNewswire
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
December 11, 2025

InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

Indeterminate GlobeNewswire
ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 11, 2025

ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference

Indeterminate GlobeNewswire
Eukarÿs Wins 2025 BioTools Innovator Grand Prize and Joins BARDA’s Elite VANGUARD Program
December 11, 2025

Eukarÿs Wins 2025 BioTools Innovator Grand Prize and Joins BARDA’s Elite VANGUARD Program

Indeterminate GlobeNewswire
Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy
December 11, 2025

Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy

Indeterminate GlobeNewswire
Tech Town in North China's Tianjin Fosters Emerging Powerhouses in Biomedical Sector
December 11, 2025

Tech Town in North China's Tianjin Fosters Emerging Powerhouses in Biomedical Sector

Indeterminate GlobeNewswire
Bio Usawa Welcomes Global Health Strategist, Professor Prashant Yadav, as Chair of Its Global Access and Health Equity Advisory Board
December 11, 2025

Bio Usawa Welcomes Global Health Strategist, Professor Prashant Yadav, as Chair of Its Global Access and Health Equity Advisory Board

Indeterminate GlobeNewswire
Aukera Therapeutics Comes Out of Stealth
December 11, 2025

Aukera Therapeutics Comes Out of Stealth

Indeterminate GlobeNewswire
Basilea und Phare Bio gehen Partnerschaft zur Entwicklung eines neuartigen Antibiotikums ein - Kombination von industrieller Expertise und einzigartigen KI-Fähigkeiten
December 11, 2025

Basilea und Phare Bio gehen Partnerschaft zur Entwicklung eines neuartigen Antibiotikums ein - Kombination von industrieller Expertise und einzigartigen KI-Fähigkeiten

Indeterminate GlobeNewswire
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
December 11, 2025

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Indeterminate GlobeNewswire
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
December 11, 2025

Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

Indeterminate GlobeNewswire
Sequana Medical Announces U.S. Commercial alfapump® Implantations at University of Pennsylvania
December 11, 2025

Sequana Medical Announces U.S. Commercial alfapump® Implantations at University of Pennsylvania

Indeterminate GlobeNewswire
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
December 11, 2025

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Indeterminate GlobeNewswire
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
December 11, 2025

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

Indeterminate GlobeNewswire
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares
December 11, 2025

Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares

Indeterminate GlobeNewswire
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
December 11, 2025

BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update

Indeterminate GlobeNewswire
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
December 11, 2025

MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions